James Peyer - Mar 23, 2021 Form 4/A - Amendment Insider Report for Sensei Biotherapeutics, Inc. (SNSE)

Role
Director, 10%+ Owner
Signature
/s/ Sarah Field, Attorney-in-Fact
Stock symbol
SNSE
Transactions as of
Mar 23, 2021
Transactions value $
$136,230
Form type
4/A - Amendment
Date filed
4/21/2022, 04:25 PM
Date Of Original Report
Mar 24, 2021
Previous filing
Apr 21, 2022
Next filing
Dec 20, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SNSE Common Stock Purchase $136K +9.5K +0.2% $14.34* 4.8M Mar 23, 2021 See footnote F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This Form 4 is being amended to correct the number of shares purchased. The original Form 4 filed on March 24, 2021, overstated the number of shares purchased.
F2 The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $14.00 to $14.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.
F3 These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.